| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3030736 | Trends in Cardiovascular Medicine | 2009 | 4 Pages |
Phospholipase A2s (PLA2s) produce free fatty acid and lysophospholipid from membrane phospholipid, and these products can be converted into various types of proinflammatory lipid mediators by specific enzymes. Among several types of PLA2, secretory PLA2s (sPLA2s) have crucial roles in the development of cardiovascular diseases. Circulating sPLA2 is increasing in patients with coronary artery disease (CAD), and it can be a risk factor for CAD and a prognostic factor in those patients. Secretory PLA2s amplify the inflammatory responses in myocardial ischemia/reperfusion injury and fetal acute respiratory distress. In some animal experiments, sPLA2s can hydrolyze low-density lipoprotein and high-density lipoprotein and lead to progress of atherosclerotic plaques. Some inhibitor studies for sPLA2 revealed that inhibition of sPLA2 reduced the myocardial impairment after ischemia/reperfusion injury and progression of atherosclerotic plaque areas in animal models. Secretory PLA2s might be a new target for cardiovascular medicine.
